AbbVie Awards 20 Individuals Living With Migraine To Support Career Aspirations
AbbVie Migraine Career Catalyst Award™ contest winners shared inspiring stories and professional goals, showcasing their triumphs over the challenges of living with migraine AbbVie, a leader in mig...
AbbVie's disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
AbbVie's “pain” is Bristol Myers Squibb's “gain,” says Truist Securities analyst Srikripa Devarakonda.
AbbVie And Pfizer: Q3 Dividend Checkup Post-Earnings
I review both AbbVie and Pfizer's recent earnings reports via the window of dividends following Peter Lynch's wisdom. Lynch's insights into dividend stocks are often in the shadow of his reputation...
AbbVie Stock: Keep Calm And Buy The Dip
AbbVie shares dropped nearly 10% after its schizophrenia drug emraclidine failed in late-stage trials. The market reaction appears excessive and presents a buying opportunity. Dividend yield and ro...
AbbVie Stock Sinks After Schizophrenia Drug Trials Disappoint
Shares of AbbVie (ABBV) plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pair of Phase 2 clinical trials.
AbbVie sheds $38bn in value after failing schizophrenia drug trials
Pharma giant AbbVie Inc has disclosed that Phase 2 trials of its emraclidine schizophrenia treatment have failed to meet their primary endpoint objectives. The treatment did not show a significant ...
3 Spectacular High-Yield Dividend Stocks to Buy in November
High yields aren't a warning indicator with these three stocks.
2 Dividend Kings That Would Have Doubled Your Money in 5 Years
You can be a little greedy sometimes and find great stocks that possess solid growth prospects and also pay dividends.
Dividend Watch: Three Companies Boosting Quarterly Payouts
Earnings season continues to move at a rapid pace, with many companies reporting daily. And recently, these three companies delivered news of higher dividend payouts.
High-Yield AbbVie Gains Momentum: A 20% Upside Is in Sight
The story with AbbVie NYSE: ABBV in 2024 is that it fell off a patent cliff but survived. It survived and continues to thrive because of its strengths in its core immunology portfolio and diversifi...
5 Stocks That Recently Announced Dividend Hikes
Investors may keep a tab on stocks like COP, BERY, HII, ABBV and ASB, which have lately hiked their dividend payments.
AbbVie (ABBV) Surpasses Q3 Earnings and Revenue Estimates
AbbVie (ABBV) came out with quarterly earnings of $3 per share, beating the Zacks Consensus Estimate of $2.92 per share. This compares to earnings of $2.95 per share a year ago.
AbbVie Reports Third-Quarter 2024 Financial Results
Reports Third-Quarter Diluted EPS of $0.88 on a GAAP Basis, a Decrease of 12.0 Percent; Adjusted Diluted EPS of $3.00, an Increase of 1.7 Percent; These Results Include an Unfavorable Impact of $0....
Will These 5 Big Drug Stocks Surpass Q3 Earnings Forecasts?
Let's look at five pharma and drug companies, PFE, LLY, ABBV, MRK and BMY, that are scheduled to release their third-quarter 2024 results this week.
Related Companies